EUVIMEDEUVIMED entdecken
Crossref

Specifically Enhanced Immunosuppression of B Cells with Chimeric Antigen Receptors Modify Mesenchymal Stem Cells

Xiaoyan Zhao, Jingxi Gao, Xingyu Zhu, Yunhua Chen, Hui Ge, Yuzhen Xiao, Qin Han, Zhao Sun, Xiuli Zhao, Robert Chunhua Zhao iD

Stem Cells and Development · 2025

DOI: 10.1089/scd.2025.0021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells and Development, 2025. Verfasst von Xiaoyan Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Basic Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Receptors, Chimeric Antigen, B-Lymphocytes, Immunosuppression Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, cell therapies, including chimeric antigen receptor (CAR) modified T cell therapy and mesenchymal stem cell (MSC) therapy, have demonstrated considerable potential for systemic lupus erythematosus (SLE). In this study, a CAR-MSC model was constructed, combining two cell therapies. The structural domains of the CAR were designed by using the anti-CD19 scFv, targeting the CD19 antigen on the surface of B cells and the intracellular region of the interferon-gamma receptor, activating the JAK-STAT1 signaling pathway. Then we screened and identified the most effective structural domain of CAR as CAR1, as it facilitates MSCs to maintain significantly higher levels of JAK2 phosphorylation and IDO expression, as shown by western blot analysis. We also demonstrated CAR1 could be consistently and stably expressed at high levels in MSCs, and CAR1 transduction did not significantly affect the surface antigenic phenotypic criteria of MSCs via flow analysis. Furthermore, immunofluorescence results showed CAR1-MSCs could stably bind CD19 antigen, and they were activated by human CD19 antigen resulting in significantly high JAK2 phosphorylation and IDO expression via western blot analysis following co-culture. Besides, when activated peripheral blood mononuclear cells (PBMCs) were co-cultured with untransduced MSCs (UTD-MSCs) and CAR1-MSCs in vitro, respectively, the results showed that the percentage of activated CD3+ T cells and CD19+ B cells was both significantly lower after co-culturing. The percentage of activated CD19+ B cells was lower in the CAR1-MSCs co-culture group than in the UTD-MSCs co-culture group, whereas the percentage of activated CD3+ T cells was similar in the two co-culture groups. This suggests that CAR1 increased the inhibitory ability of MSCs on activated CD19+ B cells and had no significant effect on the ability of MSCs to inhibit activated CD3+ T cells. In conclusion, CAR1-MSCs were successfully constructed and demonstrated the ability to enhance the inhibitory effect of MSCs on activated human CD19+ B cells, facilitating SLE therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsReceptors, Chimeric AntigenB-LymphocytesImmunosuppression TherapyHumansAntigens, CD19Coculture TechniquesJanus Kinase 2Signal TransductionPhosphorylationLupus Erythematosus, SystemicReceptors, InterferonT-Lymphocytes

Stichwörter der Autor:innen

CAR-MSCMSCSLEcell therapyimmunomodulation

Substanzen

Receptors, Chimeric AntigenAntigens, CD19Janus Kinase 2Receptors, Interferon

Autor:innen und Institutionen

  • Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Basic Medical Sciences, Beijing, China.
  • Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

ORCID-Profile: Robert Chunhua Zhao

Zitieren

APA

Zhao, X., Gao, J., Zhu, X., Chen, Y., Ge, H., Xiao, Y., Han, Q., Sun, Z., Zhao, X., & Zhao, R. C. (2025). Specifically Enhanced Immunosuppression of B Cells with Chimeric Antigen Receptors Modify Mesenchymal Stem Cells. Stem Cells and Development. https://doi.org/10.1089/scd.2025.0021

Vancouver

Zhao X, Gao J, Zhu X, Chen Y, Ge H, Xiao Y, et al. Specifically Enhanced Immunosuppression of B Cells with Chimeric Antigen Receptors Modify Mesenchymal Stem Cells. Stem Cells and Development. 2025. doi:10.1089/scd.2025.0021

BibTeX
@article{Zhao2025,
  author = {Zhao, Xiaoyan and Gao, Jingxi and Zhu, Xingyu and Chen, Yunhua and Ge, Hui and Xiao, Yuzhen and Han, Qin and Sun, Zhao and Zhao, Xiuli and Zhao, Robert Chunhua},
  title = {Specifically Enhanced Immunosuppression of B Cells with Chimeric Antigen Receptors Modify Mesenchymal Stem Cells},
  journal = {Stem Cells and Development},
  year = {2025},
  doi = {10.1089/scd.2025.0021}
}
Kostenlos starten →